Hikma's Levomilnacipran Hydrochloride ANDA210732 Receives AP Status
The FDA has granted Abbreviated Approval (AP) status for Hikma's ANDA210732 for Levomilnacipran Hydrochloride.
Therapeutic Area
Therapeutic area intelligence for SNRI with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No related entities indexed yet.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.